thyroxine has been researched along with Skin Neoplasms in 26 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies." | 8.83 | Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. ( Assaf, C; Bagot, M; Dummer, R; Duvic, M; Gniadecki, R; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S, 2006) |
| "Bexarotene is a specific retinoid X receptor agonist that has been used for the treatment of cutaneous T-cell lymphoma (CTCL)." | 8.12 | Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. ( Cayrol, F; Cerchietti, L; Cremaschi, GA; Debernardi, M; Díaz Flaqué, MC; Magro, C; Marullo, R; Mulvey, E; Paulazo, A; Phillip, JM; Revuelta, MV; Ruan, J; Sterle, H; Zamponi, N, 2022) |
| "Bexarotene-induced central hypothyroidism (CH), for which levothyroxine (LT4) replacement is recommended, has been shown to be caused by pituitary but not hypothalamic disorder experimentally, though the underlying mechanism in humans remains unclear." | 8.12 | Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. ( Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S, 2022) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 5.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| "Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies." | 4.83 | Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. ( Assaf, C; Bagot, M; Dummer, R; Duvic, M; Gniadecki, R; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S, 2006) |
| "Bexarotene is a specific retinoid X receptor agonist that has been used for the treatment of cutaneous T-cell lymphoma (CTCL)." | 4.12 | Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. ( Cayrol, F; Cerchietti, L; Cremaschi, GA; Debernardi, M; Díaz Flaqué, MC; Magro, C; Marullo, R; Mulvey, E; Paulazo, A; Phillip, JM; Revuelta, MV; Ruan, J; Sterle, H; Zamponi, N, 2022) |
| "Bexarotene-induced central hypothyroidism (CH), for which levothyroxine (LT4) replacement is recommended, has been shown to be caused by pituitary but not hypothalamic disorder experimentally, though the underlying mechanism in humans remains unclear." | 4.12 | Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. ( Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S, 2022) |
| "Bexarotene produce as predictable side effects severe mixed hyperlipidemia with marked decrease in HDL-cholesterol levels and central hypothyroidism, being the both reversible and dose-dependent." | 3.83 | [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma]. ( Garcia Morillo, JS; Muñiz Grijalvo, O; Pamies Andreu, E; Rodriguez Suarez, S, 2016) |
| "A 54-year-old woman with myxedema had hundreds of discrete cutaneous mucinous papules, which responded dramatically to appropriate replacement therapy with L-thyroxine." | 3.66 | Multiple cutaneous focal mucinoses with hypothyroidism. ( Jakubovic, HR; Rosenthal, D; Salama, SS, 1982) |
| "Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL." | 2.44 | CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature. ( Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A, 2008) |
| "Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs)." | 1.51 | Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. ( Fujii, T; Hishizawa, M; Inagaki, N; Kawaguchi-Sakita, N; Kim, YH; Kitamura, M; Kitawaki, T; Matsumoto, S; Nomura, M; Otsuka, A; Saito, R; Sakamori, Y; Sone, M; Taura, D; Yamasaki, T; Yamauchi, I; Yasoda, A, 2019) |
| "The prevalence of halo nevi was significantly higher (P < 0." | 1.46 | Effects of age of onset on disease characteristics in non-segmental vitiligo. ( Cosansu, NC; Dikicier, BS; Erdem, T; Solak, B, 2017) |
| "They had similar clinical (macrocephaly, broad faces, skin tags, motor dyspraxia, slow speech), biochemical (subnormal ratio of free thyroxine:free tri-iodothyronine [T3], low concentration of total reverse T3, high concentration of creatine kinase, mild anaemia), and radiological (thickened calvarium) features to patients with TRα1-mediated resistance to thyroid hormone, although our patients had a heterozygous mis-sense mutation (Ala263Val) in both TRα1 and TRα2 proteins." | 1.40 | Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)α1 and TRα2: clinical, biochemical, and genetic analyses of three related patients. ( Agostini, M; Aylwin, S; Buchanan, C; Chatterjee, KK; Chrysis, D; Efthymiadou, A; Gurnell, M; Halsall, D; Lyons, G; Moran, C; Offiah, AC; Poole, K; Rajanayagam, O; Schoenmakers, E; Schoenmakers, N; Visser, WE, 2014) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 1.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| "Vitiligo is the most common pigmentation-related disorder worldwide." | 1.37 | Relevance of autoimmune thyroiditis in children and adolescents with vitiligo. ( Alpay, K; Bahadır, S; Okten, A; Uncu, S; Yaylı, S, 2011) |
| "He had had recent chemotherapy for Merkel cell carcinoma of the right ear." | 1.34 | Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. ( Hassoun, A; Ibrahim, F, 2007) |
| "The patient presented recurrences of metastatic skin nodules, lung and bone metastases, and died after a 3-year follow-up." | 1.29 | Cutaneous metastasis from follicular carcinoma of the thyroid gland. ( Bazex, J; Caron, P; Gorguet, B; Moreau-Cabarrot, A, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (19.23) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 10 (38.46) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Cayrol, F | 1 |
| Revuelta, MV | 1 |
| Debernardi, M | 1 |
| Paulazo, A | 1 |
| Phillip, JM | 1 |
| Zamponi, N | 1 |
| Sterle, H | 1 |
| Díaz Flaqué, MC | 1 |
| Magro, C | 1 |
| Marullo, R | 1 |
| Mulvey, E | 1 |
| Ruan, J | 1 |
| Cremaschi, GA | 1 |
| Cerchietti, L | 1 |
| Piccerillo, A | 1 |
| El Hachem, M | 1 |
| De Vito, R | 1 |
| De Luca, EV | 1 |
| Peris, K | 1 |
| Toi, N | 1 |
| Kurajoh, M | 1 |
| Miyaoka, D | 1 |
| Nagata, Y | 1 |
| Yamada, S | 1 |
| Imanishi, Y | 1 |
| Hayashi, D | 1 |
| Tateishi, C | 1 |
| Inaba, M | 1 |
| Tsuruta, D | 1 |
| Morita, A | 1 |
| Emoto, M | 1 |
| Yamauchi, I | 2 |
| Sakane, Y | 1 |
| Fukuda, Y | 1 |
| Fujii, T | 2 |
| Taura, D | 2 |
| Hirata, M | 1 |
| Hirota, K | 1 |
| Ueda, Y | 1 |
| Kanai, Y | 1 |
| Yamashita, Y | 1 |
| Kondo, E | 1 |
| Sone, M | 2 |
| Yasoda, A | 2 |
| Inagaki, N | 2 |
| Ansorge, C | 1 |
| Seufert, J | 1 |
| Meiss, F | 1 |
| von Bubnoff, D | 1 |
| Peiró, I | 1 |
| Palmero, R | 1 |
| Iglesias, P | 1 |
| Díez, JJ | 1 |
| Simó-Servat, A | 1 |
| Marín, JA | 1 |
| Jiménez, L | 1 |
| Domingo-Domenech, E | 1 |
| Mancho-Fora, N | 1 |
| Nadal, E | 1 |
| Villabona, C | 1 |
| Matsumoto, S | 1 |
| Sakamori, Y | 1 |
| Kim, YH | 1 |
| Nomura, M | 1 |
| Otsuka, A | 1 |
| Yamasaki, T | 1 |
| Saito, R | 1 |
| Kitamura, M | 1 |
| Kitawaki, T | 1 |
| Hishizawa, M | 1 |
| Kawaguchi-Sakita, N | 1 |
| Moran, C | 1 |
| Agostini, M | 1 |
| Visser, WE | 1 |
| Schoenmakers, E | 1 |
| Schoenmakers, N | 1 |
| Offiah, AC | 1 |
| Poole, K | 1 |
| Rajanayagam, O | 1 |
| Lyons, G | 1 |
| Halsall, D | 1 |
| Gurnell, M | 1 |
| Chrysis, D | 1 |
| Efthymiadou, A | 1 |
| Buchanan, C | 1 |
| Aylwin, S | 1 |
| Chatterjee, KK | 1 |
| Rodriguez Suarez, S | 1 |
| Pamies Andreu, E | 1 |
| Muñiz Grijalvo, O | 1 |
| Garcia Morillo, JS | 1 |
| Solak, B | 1 |
| Dikicier, BS | 1 |
| Cosansu, NC | 1 |
| Erdem, T | 1 |
| Gopaluni, S | 1 |
| Perzova, R | 1 |
| Abbott, L | 1 |
| Farah, R | 1 |
| Shrimpton, A | 1 |
| Hutchison, R | 1 |
| Poiesz, BJ | 1 |
| Ghannoum, JE | 1 |
| Odingo, NA | 1 |
| Provost, N | 1 |
| Uncu, S | 1 |
| Yaylı, S | 1 |
| Bahadır, S | 1 |
| Okten, A | 1 |
| Alpay, K | 1 |
| Avagyan, S | 1 |
| Klein, M | 1 |
| Kerkar, N | 1 |
| Demattia, A | 1 |
| Blei, F | 1 |
| Lee, S | 1 |
| Rosenberg, HK | 1 |
| Arnon, R | 1 |
| Scarisbrick, JJ | 1 |
| Morris, S | 1 |
| Azurdia, R | 1 |
| Illidge, T | 1 |
| Parry, E | 1 |
| Graham-Brown, R | 1 |
| Cowan, R | 1 |
| Gallop-Evans, E | 1 |
| Wachsmuth, R | 1 |
| Eagle, M | 1 |
| Wierzbicki, AS | 1 |
| Soran, H | 1 |
| Whittaker, S | 2 |
| Wain, EM | 1 |
| FLECK, F | 1 |
| MEITES, J | 1 |
| STOLK, A | 1 |
| Assaf, C | 1 |
| Bagot, M | 1 |
| Dummer, R | 1 |
| Duvic, M | 1 |
| Gniadecki, R | 1 |
| Knobler, R | 1 |
| Ranki, A | 2 |
| Schwandt, P | 1 |
| Hassoun, A | 1 |
| Ibrahim, F | 1 |
| Jakubovic, HR | 1 |
| Salama, SS | 1 |
| Rosenthal, D | 1 |
| Lupulescu, A | 1 |
| Caron, P | 1 |
| Moreau-Cabarrot, A | 1 |
| Gorguet, B | 1 |
| Bazex, J | 1 |
| Loureiro, MM | 1 |
| Leite, VH | 1 |
| Boavida, JM | 1 |
| Raposo, JF | 1 |
| Henriques, MM | 1 |
| Limbert, ES | 1 |
| Sobrinho, LG | 1 |
| Phan, GQ | 1 |
| Attia, P | 1 |
| Steinberg, SM | 1 |
| White, DE | 1 |
| Rosenberg, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus in the Treatment for Propranolol-resistant Infantile Hepatic Hemangioendothelioma[NCT04406870] | Phase 4 | 36 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma[NCT03918252] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-02 | Recruiting | ||
| Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.[NCT02259621] | Phase 2 | 45 participants (Anticipated) | Interventional | 2014-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thyroxine and Skin Neoplasms
| Article | Year |
|---|---|
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Co | 2008 |
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Topics: Anticarcinogenic Agents; Bexarotene; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; | 2006 |
24 other studies available for thyroxine and Skin Neoplasms
| Article | Year |
|---|---|
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Humans; Integrin alphaVbeta3; Lymphoma, | 2022 |
Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B7-H1 Antigen; Carci | 2020 |
Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients.
Topics: Bexarotene; Humans; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Retrospective Studies; Skin Neoplas | 2022 |
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lung Neoplasm | 2017 |
Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
Topics: Adult; Antineoplastic Agents, Immunological; Autoimmune Hypophysitis; Humans; Hydrocortisone; Hypopi | 2018 |
Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Hodgkin D | 2019 |
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxygluco | 2019 |
Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)α1 and TRα2: clinical, biochemical, and genetic analyses of three related patients.
Topics: Adult; Alternative Splicing; Amino Acid Substitution; Family Health; Female; Gait Apraxia; Heterozyg | 2014 |
[Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Chol | 2016 |
Effects of age of onset on disease characteristics in non-segmental vitiligo.
Topics: Adolescent; Adult; Age of Onset; Aged; Antibodies, Antinuclear; Autoantibodies; Autoimmune Diseases; | 2017 |
Clinico-pathologic conference: case 6.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Carcinoma, Squamous Cell; | 2009 |
Relevance of autoimmune thyroiditis in children and adolescents with vitiligo.
Topics: Adolescent; Age of Onset; Autoantibodies; Child; Child, Preschool; Comorbidity; Female; Humans; Inci | 2011 |
Propranolol as a first-line treatment for diffuse infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-2 Receptor Antagonists; Antineoplastic Agents; Congenital Hypothyroidism; Drug Monit | 2013 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, | 2013 |
[Treatment of roentgen carcinoma by hypervitaminization with axerophtholen].
Topics: Carcinoma; Humans; Skin Neoplasms; Thyroxine; Vitamin A | 1954 |
Effects of thyroxine and thiouracil on induction of skin tumors in mice by 9,10-dimethyl-1,2-benzanthracene and croton oil.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anthracenes; Benz(a)Anthracenes; Carcinogens; Croton Oil; | 1958 |
Effect of thiouracil and thyroxine on development and growth of cutaneous melanoma in killifish hybrids.
Topics: Animals; Fundulidae; Growth and Development; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Expe | 1959 |
Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis.
Topics: Aged; Anti-Bacterial Agents; Carcinoma, Merkel Cell; Clostridioides difficile; Cytotoxins; Diarrhea; | 2007 |
Bexarotene combination therapy for patients with Sézary syndrome.
Topics: Antineoplastic Agents; Atorvastatin; Bexarotene; Drug Therapy, Combination; Heptanoic Acids; Humans; | 2008 |
Multiple cutaneous focal mucinoses with hypothyroidism.
Topics: Female; Humans; Hypothyroidism; Middle Aged; Mucins; Myxedema; Skin; Skin Neoplasms; Thyroxine | 1982 |
Hormonal regulation of epidermal tumor development.
Topics: Animals; Calcitonin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; DNA Replication; Estradiol; Ho | 1981 |
Cutaneous metastasis from follicular carcinoma of the thyroid gland.
Topics: Adenocarcinoma, Follicular; Aged; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Melanoma; R | 1993 |
An unusual case of papillary carcinoma of the thyroid with cutaneous and breast metastases only.
Topics: Biopsy, Needle; Breast Neoplasms; Carcinoma, Papillary; Female; Humans; Iodine Radioisotopes; Middle | 1997 |
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Inject | 2001 |
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Inject | 2001 |
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Inject | 2001 |
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Inject | 2001 |